Evidence map›Paper›PMID 26122609›Full record

ReviewMicrobial cell factories2015

Yeast as a cell factory: current state and perspectives.

Martin Kavšček, Martin Stražar, Tomaž Curk, Klaus Natter, Uroš Petrovič

Abstract readReview
In one paragraph

Review in Microbial cell factories, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed.

  1. Article
  2. Metabolic Engineering ofChem & bio engineering · 2026
    Article
  3. The Alleviating Effect of Arginine on Ethanol Stress inJournal of fungi (Basel, Switzerland) · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. ACS synthetic biology · 2023
    Article
  20. A comprehensive review and comparison of L-tryptophan biosynthesis inFrontiers in bioengineering and biotechnology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Martin KavščekInstitute of Molecular Biosciences, University of Graz, Humboldtstrasse 50/II, 8010, Graz, Austria. martin.kavscek@uni-graz.at.
Martin StražarFaculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia. martin.strazar@fri.uni-lj.si.
Tomaž CurkFaculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia. tomaz.curk@fri.uni-lj.si.
Klaus NatterInstitute of Molecular Biosciences, University of Graz, Humboldtstrasse 50/II, 8010, Graz, Austria. klaus.natter@uni-graz.at.
Uroš PetrovičDepartment of Molecular and Biomedical Sciences, Jožef Stefan Institute, Jamova 39, 1000, Ljubljana, Slovenia. uros.petrovic@ijs.si.

Funding

Austrian Science Fund FWF TRP 240
6 · The paper itself

Abstract

The yeast Saccharomyces cerevisiae is one of the oldest and most frequently used microorganisms in biotechnology with successful applications in the production of both bulk and fine chemicals. Yet, yeast researchers are faced with the challenge to further its transition from the old workhorse to a modern cell factory, fulfilling the requirements for next generation bioprocesses. Many of the principles and tools that are applied for this development originate from the field of synthetic biology and the engineered strains will indeed be synthetic organisms. We provide an overview of the most important aspects of this transition and highlight achievements in recent years as well as trends in which yeast currently lags behind. These aspects include: the enhancement of the substrate spectrum of yeast, with the focus on the efficient utilization of renewable feedstocks, the enhancement of the product spectrum through generation of independent circuits for the maintenance of redox balances and biosynthesis of common carbon building blocks, the requirement for accurate pathway control with improved genome editing and through orthogonal promoters, and improvement of the tolerance of yeast for specific stress conditions. The causative genetic elements for the required traits of the future yeast cell factories will be assembled into genetic modules for fast transfer between strains. These developments will benefit from progress in bio-computational methods, which allow for the integration of different kinds of data sets and algorithms, and from rapid advancement in genome editing, which will enable multiplexed targeted integration of whole heterologous pathways. The overall goal will be to provide a collection of modules and circuits that work independently and can be combined at will, depending on the individual conditions, and will result in an optimal synthetic host for a given production process.

Indexed as

Industrial MicrobiologyMetabolic EngineeringSaccharomyces cerevisiae

Identifiers

PMID26122609
PMCPMC4486425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.